Growth Metrics

Quest Diagnostics (DGX) EBIT: 2009-2025

Historic EBIT for Quest Diagnostics (DGX) over the last 17 years, with Sep 2025 value amounting to $386.0 million.

  • Quest Diagnostics' EBIT rose 16.97% to $386.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year increase of 22.28%. This contributed to the annual value of $1.3 billion for FY2024, which is 6.66% up from last year.
  • Per Quest Diagnostics' latest filing, its EBIT stood at $386.0 million for Q3 2025, which was down 11.87% from $438.0 million recorded in Q2 2025.
  • In the past 5 years, Quest Diagnostics' EBIT registered a high of $660.0 million during Q1 2021, and its lowest value of $135.0 million during Q4 2022.
  • Moreover, its 3-year median value for EBIT was $346.0 million (2025), whereas its average is $343.5 million.
  • In the last 5 years, Quest Diagnostics' EBIT soared by 277.14% in 2021 and then crashed by 74.81% in 2022.
  • Over the past 5 years, Quest Diagnostics' EBIT (Quarterly) stood at $536.0 million in 2021, then plummeted by 74.81% to $135.0 million in 2022, then surged by 97.78% to $267.0 million in 2023, then spiked by 35.21% to $361.0 million in 2024, then increased by 16.97% to $386.0 million in 2025.
  • Its last three reported values are $386.0 million in Q3 2025, $438.0 million for Q2 2025, and $346.0 million during Q1 2025.